Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2026 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to Corcept Therapeutics First Quarter 2026 Earnings Conference Call.
Corcept Therapeutics Inc (CORT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 233 | $9,392 | -96% | 0.01% |
| 2. | Hurley Capital Charles Goldblum | 100 | $4,031 | 0% | |
| 3. | Leucadia National Ian Cumming And Joseph Steinberg | 0 | $0 | 0% | |
| 4. | Prescott Group Capital Management Phil Frohlich | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $33.56 | 24,218 | $812,836.00 | 1,146,631 | 2026-03-17 | Filing | |
| $33.00 | 75,782 | $2,500,972.72 | 1,122,413 | 2026-03-17 | Filing | |
| $21.53 | 100,000 | $2,153,000.00 | 3,308,303 | 2021-06-11 | Filing | |
| $21.53 | 50,000 | $1,076,500.00 | 1,046,838 | 2021-06-11 | Filing | |
| $22.64 | 68 | $1,539.52 | 3,208,303 | 2020-12-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $51.83 | 20,000 | $1,036,600.00 | 2,231 | 2026-05-05 | Filing | |
| $50.10 | 40,000 | $2,003,860.00 | 2,878,326 | 2026-05-01 | Filing | |
| $40.97 | 20,000 | $819,400.00 | 2,231 | 2026-04-07 | Filing | |
| $50.07 | 26,198 | $1,311,825.55 | 2,918,326 | 2026-03-25 | Filing | |
| $36.01 | 11,767 | $423,729.67 | 2,231 | 2026-03-20 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,820,568 | $194,317,096 | 0.01% | |
| 2. | 4,077,196 | $164,351,771 | 0% | |
| 3. | 3,977,404 | $160,329,155 | 2.88% | |
| 4. | 1,553,135 | $62,596,749 | 0.01% | |
| 5. | 1,363,668 | $54,969,457 | 0.01% |
News See All
Corcept (CORT) Upgraded After Key Regulatory Approval for Lifyorli
Corcept Therapeutics Incorporated (NASDAQ:CORT) ranks among the most profitable biotech stocks to buy now.
10 Most Profitable Biotech Stocks to Buy Now
Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, surpassing both the S&P 500 and the broader market index, and ending 2025 with its...
10 Best Biotech Stocks with Highest Upside Potential
On April 16, reports from J.P. Morgan's biopharma and medtech venture and licensing studies indicated that the capital markets began the year 2026 with selective strength.
7 Best Stocks to Buy for Short Term
In a continuously evolving market, investing has become a game of timing and informed decision-making.
Corcept Therapeutics (CORT) Climbs 19.7% as Lifyorli Gets FDA OK
Corcept Therapeutics rallied for a second day on Wednesday, soaring 19.66 percent to finish at $40.47 apiece, as investors snapped up shares after securing the green light of the Food and Drug Administration...
10 Stocks Investors Are Buying Now: Chewy, Braze, Sarepta, and More
The company said that it has begun recruiting highly-skilled German talent to operationalize its upcoming satellite manufacturing facility in Berlin, as part of its plan to double the production capacity...
H.C. Wainwright Cuts Corcept Therapeutics Incorporated (CORT) Price Target, Keeps Buy Rating
The company reported Q4 2025 revenue of $202.1 million, which fell short of the consensus estimate of $254.9 million.
12 Best Under-the-Radar Stocks to Buy According to Hedge Funds
On March 6, Reuters reported that US and European stock markets ended a volatile week with losses of over 1% as rising geopolitical tensions pushed oil prices higher.
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2025 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2025 Earnings Call Transcript February 24, 2026Corcept Therapeutics Incorporated misses on earnings expectations.
Hedge Fund Resource Center